Media365
Drugmaker Natco Pharma on Tuesday said it intends to launch its generic version of spinal muscular atrophy drug Risdiplam only after and subject to successful clarity from the Appellate Bench of the Delhi High Court on an appeal filed by Roche against a single judge’s order.
A single judge of the Delhi High Court had through an order dated March 24, 2025, denied Roche’s plea for an injunction against the company for the drug. Consequently, Roche appealed the decision before the Appellate Bench that has currently directed to maintain the status quo, Natco Pharma said.
“Subject to the foregoing, the company has decided to price the product at ₹15,900 MRP… the company also intends to offer discount to certain deserving patients through its patient access,” Natco Pharma said. It has received numerous enquiries from investors and patients about the launch, availability and pricing of the generic version of Risdiplam in the Indian market, it said.
Natco shares closed less than 1% higher at ₹771.25 each on the BSE.
Published – April 08, 2025 09:26 pm IST
